Latest Ratios: P/E Ratio -5.1x · EV/EBITDA N/A · ROE -97.9%. (2011–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $1.1B | $1.5B | $2.4B | $1.9B | $2.9B | $9.7B | $5.8B | $3.5B | $1.8B | $13M | $66M |
| Enterprise Value | $1.4B | $1.8B | $2.8B | $2.3B | $3.1B | $9.9B | $6.0B | $3.5B | $1.8B | $76M | $100M |
| P/E Ratio → | -5.08 | — | — | — | — | 627.17 | — | — | — | — | — |
| P/S Ratio | 1.04 | 1.46 | 2.51 | 2.57 | 3.60 | 13.78 | 11.70 | 9.63 | 9.94 | 0.12 | 0.78 |
| P/B Ratio | 6.69 | 9.53 | 8.96 | 6.13 | 6.55 | 22.36 | 15.93 | 17.89 | 13.92 | — | — |
| P/FCF | — | — | 472.08 | — | 176.17 | 110.26 | — | 155.94 | — | — | — |
| P/OCF | — | — | 97.32 | — | 57.14 | 86.98 | 236.55 | 83.22 | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 1.81 | 2.94 | 3.05 | 3.91 | 14.13 | 11.97 | 9.54 | 9.71 | 0.71 | 1.19 |
| EV / EBITDA | — | — | — | — | — | 272.05 | 2393.44 | — | — | — | — |
| EV / EBIT | — | — | — | — | — | 491.21 | — | — | — | — | — |
| EV / FCF | — | — | 553.04 | — | 191.28 | 113.03 | — | 154.56 | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 52.3% | 52.3% | 52.1% | 49.2% | 51.5% | 53.5% | 52.2% | 53.6% | 48.9% | 41.0% | 28.0% |
| Operating Margin | -7.7% | -7.7% | -10.5% | -31.2% | -11.6% | 3.2% | -1.6% | -4.6% | -24.3% | -58.5% | -92.6% |
| Net Profit Margin | -20.2% | -20.2% | -10.2% | -29.8% | -11.8% | 2.2% | -6.9% | -6.8% | -66.7% | -67.9% | -99.0% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -97.9% | -97.9% | -33.3% | -59.1% | -21.7% | 3.9% | -12.3% | -15.2% | -240.1% | — | -290.0% |
| ROA | -22.1% | -22.1% | -10.0% | -22.2% | -9.7% | 1.9% | -6.6% | -9.3% | -81.3% | -70.3% | -70.3% |
| ROIC | -10.0% | -10.0% | -11.1% | -25.8% | -10.2% | 2.9% | -1.8% | -9.9% | -54.4% | -152.2% | -149.3% |
| ROCE | -11.5% | -11.5% | -13.4% | -28.4% | -11.2% | 3.3% | -1.9% | -9.1% | -44.8% | -89.8% | -87.0% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 2.86 | 2.86 | 1.80 | 1.33 | 0.95 | 0.73 | 0.62 | 0.10 | — | — | — |
| Debt / EBITDA | — | — | — | — | — | 8.62 | 91.55 | — | — | — | — |
| Net Debt / Equity | — | 2.28 | 1.54 | 1.14 | 0.56 | 0.56 | 0.37 | -0.16 | -0.32 | — | — |
| Net Debt / EBITDA | — | — | — | — | — | 6.67 | 53.61 | — | — | — | — |
| Debt / FCF | — | — | 80.96 | — | 15.11 | 2.77 | — | -1.38 | — | — | — |
| Interest Coverage | -24.33 | -24.33 | -13.39 | -21.47 | -14.26 | 3.35 | -1.83 | -314.44 | -15.16 | -5.44 | -13.62 |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.55 | 2.55 | 2.93 | 3.83 | 5.14 | 6.15 | 6.14 | 2.78 | 2.83 | 1.78 | 2.93 |
| Quick Ratio | 2.02 | 2.02 | 2.33 | 3.02 | 4.47 | 5.63 | 5.52 | 2.28 | 2.53 | 1.03 | 2.25 |
| Cash Ratio | 1.21 | 1.21 | 1.77 | 2.40 | 3.73 | 4.73 | 4.67 | 1.78 | 1.95 | 0.39 | 1.70 |
| Asset Turnover | — | 1.15 | 0.97 | 0.78 | 0.76 | 0.78 | 0.70 | 1.11 | 0.89 | 1.13 | 0.75 |
| Inventory Turnover | 3.76 | 3.76 | 3.01 | 2.41 | 3.49 | 4.76 | 3.74 | 3.43 | 4.73 | 2.35 | 2.86 |
| Days Sales Outstanding | — | 59.53 | 44.48 | 51.53 | 52.26 | 57.51 | 60.14 | 46.93 | 69.86 | 70.53 | 48.40 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | 0.2% | — | — | — | — | — |
| FCF Yield | — | — | 0.2% | — | 0.6% | 0.9% | — | 0.6% | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 1.3% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 1.3% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $67M | $65M | $65M | $64M | $64M | $61M | $59M | $48M | $6M | $3M |
Liquidity and competitive pressure
Based on current market data, TNDM trades at a price-to-sales ratio of 1.10, which appears to discount the company's lack of GAAP profitability compared to the premium multiples commanded by more established peers like DexCom and Insulet, suggesting a market valuation heavily contingent on future product adoption.
The negative P/E ratio of -5.34 highlights the company's current inability to generate consistent earnings, forcing investors to rely on revenue-based multiples that may not capture the underlying cash burn. This valuation gap relative to peers suggests that the market is pricing TNDM as a speculative growth entity rather than a mature medical device manufacturer.
As reported in recent financial statements, TNDM's ROIC has remained consistently negative, bottoming out at -14.4% in 2025Q1, which indicates that the company is currently destroying shareholder value rather than compounding it through its heavy investments in hardware development and market expansion efforts.
The persistent negative returns on capital suggest that the company's high fixed-cost base and R&D spending are not yet yielding the necessary scale to drive profitability. Investors should monitor whether the transition to the Mobi platform can improve capital efficiency, as current trends show a significant struggle to generate positive returns on invested capital.
According to quarterly filings, TNDM's cash conversion cycle has fluctuated significantly, reaching a high of 148 days in 2024Q1, which reflects substantial inefficiencies in inventory management and collection cycles compared to the more streamlined operations typically observed in the broader medical device sector.
The elevated days inventory outstanding, which peaked at 146 days in 2024Q1, suggests that the company may be struggling with inventory obsolescence or overstocking as it navigates product transitions. This lack of working capital optimization further strains the company's liquidity position, as cash remains tied up in hardware that has yet to be converted into recurring supply revenue.
Based on the company's latest balance sheet data, the debt-to-equity ratio has surged to 5.55 in 2026Q1, a marked increase from 1.33 in 2023Q4, which suggests that the company's reliance on debt financing has intensified as it navigates a challenging competitive landscape and persistent negative operating margins.
The negative interest coverage ratio of -7.91 in 2026Q1 warrants serious concern, as it indicates that the company's operating income is insufficient to cover its debt service obligations. This leverage profile leaves the company with limited room for error and may necessitate further dilutive financing if operational cash flow does not improve.
Investors frequently misapply the price-to-sales ratio to TNDM, which obscures the company's underlying cash burn and the high cost of customer acquisition, failing to account for the fact that hardware sales often carry lower margins than the recurring supply revenue that the business model ultimately depends upon.
Relying on P/S multiples ignores the critical reality that TNDM's growth is currently funded by debt and equity dilution rather than internal cash generation. A more appropriate metric would be the enterprise value to recurring revenue, which would better isolate the value of the installed base from the volatile and capital-intensive hardware sales segment.
Includes 30+ ratios · 15 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying TNDM stock.
Tandem Diabetes Care, Inc.'s current P/E ratio is -5.1x. This places it at the 50th percentile of its historical range.
Tandem Diabetes Care, Inc.'s return on equity (ROE) is -97.9%. The historical average is -89.3%.
Based on historical data, Tandem Diabetes Care, Inc. is trading at a P/E of -5.1x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Tandem Diabetes Care, Inc. has 52.3% gross margin and -7.7% operating margin.